Fermenta Biotech Limited
NSE: FERMENTAMarket Closed • NSE
Day range
52 week range
Fermenta Biotech Limited closed at INR486.00 (-0.1%) on volume 0.11x its 20-day average, trading 16.59% below its 52-week high.
2022-Q1
Q1 FY2022 Financial Results
PAT moved +195.5% QoQ
2026-08-05
DIVIDEND Announced
Dividend - Rs 3.75 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.28x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Biotechnology.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 05 Aug 2026 | Dividend | ₹3.75 / share | — | 05 Aug 2026 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
Fermenta Biotech LimitedFERMENTA Current stock | ₹1,393.40 | 23.46 | 0.77% | ₹96.16 | ₹7.68 | — | — |
 Praveg LimitedPRAVEG Open analysis | ₹605.31 | — | 0.22% | ₹46.00 | -₹13.00 | +17.95% | -116.67% |
 Kwality Pharmaceuticals LimitedKPL Open analysis | — | 43.57 | 0.00% | ₹162.00 | ₹26.00 | +45.95% | +116.67% |
Fermenta Biotech Limited, together with its subsidiaries, manufactures and markets chemicals, bulk drugs, and enzymes in India, Europe, the United States, and internationally. It provides pharmaceutical formulations and environmental solutions; rents and sells properties; and sports and health awareness/education services. The company also offers various variants of vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for use in various applications, such as pharmaceuticals, dietary and nutritional supplements, feed, injectables, soft gel capsules, premixes, food and beverage fortification, veterinary, feed, and rodenticides; pharmaceutical ingredients comprising phenyramidol and silicon dry powder; nutritional premixes; and enzymes for use in oleochemicals, fine chemicals, active pharmaceutical ingredients, food and fragrances, leather, and biodiesel industries. In addition, it engages in the design, engineering, procurement, and construction of water and wastewater treatment plants; and offers operations and maintenance services, as well as property development business. The company was formerly known as DIL Limited. Fermenta Biotech Limited was incorporated in 1951 and is based in Thane, India.
IndiaHealth Technology
Is Fermenta Biotech Limited Shariah compliant?
Fermenta Biotech Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2829.4%) exceeds AAOIFI threshold (≤ 33%).
What is Fermenta Biotech Limited's current valuation relative to peers?
Fermenta Biotech Limited trades at a P/E of 23.5x compared to the sector median of 33.5x, and a Price-to-Book of 3.4x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.28x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.